Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1071
Source ID: NCT03482024
Associated Drug: Tirzepatide
Title: A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT03482024/results
Conditions: Renal Insufficiency|End Stage Renal Disease
Interventions: DRUG: Tirzepatide
Outcome Measures: Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]), Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) of Tirzepatide was evaluated., Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose|PK: Maximum Concentration of Tirzepatide, Cmax is the maximum observed concentration of Tirzepatide., Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose|PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf]), Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of Tirzepatide was evaluated., Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose |
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 45
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
Start Date: 2018-03-30
Completion Date: 2019-08-19
Results First Posted: 2023-03-23
Last Update Posted: 2023-03-23
Locations: Orange County Research Center, Tustin, California, 92780, United States|Clinical Pharmacology of Miami, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|High Point Clinical Trials Center, High Point, North Carolina, 27265, United States
URL: https://clinicaltrials.gov/show/NCT03482024

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress